ClearPoint Neuro Inc. (CLPT)
CLPT moved a median of -0.42% 30 minutes after news, and -0.06% by the close. How CLPT actually reacts to news — the realized, point-in-time move the market made, measured across 337 labeled events over the last three years with zero look-ahead.
CLPT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 331 |
| 30-min | -0.42% | 43% | 334 |
| 60-min | -0.15% | 46% | 336 |
| to close | -0.06% | 49% | 335 |
| Middle 50% of CLPT reactions | -1.14% to +1.10% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 337 |
Half of all ClearPoint Neuro Inc. news events land between -1.14% and +1.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CLPT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CLPT's baseline. Nothing else.
Recent CLPT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ClearPoint Neuro, Inc. (CLPT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.05% | -1.36% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ClearPoint Neuro, Inc. (CLPT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.16% | +1.90% | |
| ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 | Press release | ACCESS Newswire | -0.11% | +5.36% | |
| ClearPoint Neuro, Inc. (CLPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.20% | -0.20% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ClearPoint Neuro, Inc. (CLPT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.19% | -1.64% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ClearPoint Neuro, Inc. (CLPT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.43% | -0.10% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ClearPoint Neuro, Inc. (CLPT) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.46% | -1.30% | |
| CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -0.99% | -0.66% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ClearPoint Neuro, Inc. (CLPT) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.14% | +2.13% | |
| ClearPoint Neuro Reports Second Quarter 2026 Results | Press release | ACCESS Newswire | -0.46% | -1.79% | |
| Form 10-Q ClearPoint Neuro, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.46% | -1.79% | |
| Form 8-K ClearPoint Neuro, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -1.79% | |
| ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel | Press release | ACCESS Newswire | +0.17% | +3.15% | |
| ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026 | Press release | ACCESS Newswire | +0.16% | -2.28% | |
| ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint | Press release | ACCESS Newswire | -2.00% | +6.16% | |
| Form 8-K ClearPoint Neuro, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +1.87% | -2.72% | |
| Form S-8 ClearPoint Neuro, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.99% | +5.79% | |
| ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint | Press release | ACCESS Newswire | +2.33% | +10.37% | |
| ClearPoint Neuro Reports First Quarter 2026 Results | Press release | ACCESS Newswire | +2.33% | +10.37% | |
| Form 10-Q ClearPoint Neuro, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.33% | +10.37% | |
| Form 8-K ClearPoint Neuro, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +2.33% | +10.37% | |
| ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026 | Press release | ACCESS Newswire | +2.50% | +8.02% | |
| Form ARS ClearPoint Neuro, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.12% | +9.58% | |
| Form DEFA14A ClearPoint Neuro, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.12% | +9.58% | |
| ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint | Press release | ACCESS Newswire | -1.81% | -2.45% | |
| ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint | Press release | ACCESS Newswire | -1.51% | -4.71% | |
| Form DEF 14A ClearPoint Neuro, Inc. For: Apr 10 | SEC filing · Form DEF | SEC EDGAR | -0.46% | +15.06% | |
| ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results | Press release | ACCESS Newswire | -5.67% | -10.65% | |
| Form 10-K ClearPoint Neuro, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.67% | -10.65% | |
| Form 8-K ClearPoint Neuro, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -5.67% | -10.65% | |
| ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026 | Press release | ACCESS Newswire | -0.89% | +11.11% | |
| Form S-8 ClearPoint Neuro, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.18% | -3.55% | |
| Form 8-K/A ClearPoint Neuro, Inc. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +5.98% | |
| Form D ClearPoint Neuro, Inc. | SEC filing · Form D | SEC EDGAR | -1.31% | -3.08% | |
| Form EFFECT ClearPoint Neuro, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.56% | +6.16% | |
| ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe | Press release | ACCESS Newswire | +1.56% | +6.16% | |
| Form S-3 ClearPoint Neuro, Inc. | SEC filing · Form S-3 | SEC EDGAR | -2.27% | -3.49% | |
| ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue | Press release | ACCESS Newswire | -2.49% | -0.06% | |
| Form 8-K ClearPoint Neuro, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -2.49% | -0.06% | |
| Form 8-K ClearPoint Neuro, Inc. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | -4.29% | -5.53% | |
| ClearPoint Neuro Completes Acquisition of IRRAS | Press release | ACCESS Newswire | +1.71% | +2.60% | |
| Form 8-K ClearPoint Neuro, Inc. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | +2.60% | |
| ClearPoint Neuro Announces Agreement to Acquire IRRAS | Press release | ACCESS Newswire | +3.54% | +5.61% | |
| ClearPoint Neuro Reports Third Quarter 2025 Results | Press release | ACCESS Newswire | +3.54% | +5.61% | |
| Form 10-Q ClearPoint Neuro, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.54% | +5.61% | |
| Form 8-K ClearPoint Neuro, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +3.54% | +5.61% | |
| ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025 | Press release | ACCESS Newswire | +0.76% | +6.48% | |
| ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles | Press release | ACCESS Newswire | -0.23% | +11.03% | |
| ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide | Press release | ACCESS Newswire | -0.07% | -1.42% | |
| ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System | Press release | ACCESS Newswire | -0.81% | +18.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CLPT section they belong to.
Where else CLPT is measured.
CLPT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ClearPoint Neuro Inc.'s median reaction calculated?
Every labeled CLPT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 337 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of CLPT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CLPT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.